Methods	Multicentre randomised controlled trial
Participants	448 FIGO Ia-Ib G2/3, FIGO Ic-IIa, FIGO I-IIa clear cell
Interventions	Immediate platinum-based chemotherapy versus treatment on progression Cisplatin dose = 75 mg/m2 Carboplatin dose = 350 mg/m2
Outcomes	DFS and OS Adverse events not reported Median follow-up: 5.5 years
Notes	Subgroup analysis examined impact of staging adequacy
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Based on minimisation
Allocation concealment (selection bias)	Low risk	Minimisation performed by central co-ordinating centres
Incomplete outcome data (attrition bias) All outcomes	Low risk	T: 6/224 (2%) C: 3/224 (1%)
Blinding of outcome assessors (detection bias)	High risk	No blinding
Selective reporting (reporting bias)	Unclear risk	Intention-to-treat analysis; all pre-specified outcomes reported